FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Kramar

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Carine A Bellera; Anne Auperin; Laurence Collette; Tienhan Sandrine Dabakuyo; Adélaïde Doussau; Thomas Filleron; Catherine Fortpied; Sophie Gourgou; Andrew Kramar; Christophe Le Tourneau; Simone Mathoulin-Pélissier; Murielle Mauer; Monia Ouali; Xavier Paoletti; Marina Pulido; Franck bonnetain
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Anja Lorch; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim Margolin; Jean-Pierre Lotz; Jose Ramon Germà-Lluch; Thomas Powles; Christian Kollmannsberger; Jörg Beyer
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
eric assenat; Frédéric Bibeau; Jean Pierre Bleuse; Evelyne Crapez-Lopez; Françoise Desseigne; Andrew Kramar; Laurent Mineur; Fabienne Portales; Emmanuelle Samalin; Simon Thezenas; Frédéric Viret; Marc Ychou
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Kramar (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Carine A Bellera; Anne Auperin; Laurence Collette; Tienhan Sandrine Dabakuyo; Adélaïde Doussau; Thomas Filleron; Catherine Fortpied; Sophie Gourgou; Andrew Kramar; Christophe Le Tourneau; Simone Mathoulin-Pélissier; Murielle Mauer; Monia Ouali; Xavier Paoletti; Marina Pulido; Franck bonnetain
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
European journal of cancer (Oxford, England : 1990) 2013;49(4):769-81.
2011: Anja Lorch; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim Margolin; Jean-Pierre Lotz; Jose Ramon Germà-Lluch; Thomas Powles; Christian Kollmannsberger; Jörg Beyer
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(16):2178-84.
2011: eric assenat; Frédéric Bibeau; Jean Pierre Bleuse; Evelyne Crapez-Lopez; Françoise Desseigne; Andrew Kramar; Laurent Mineur; Fabienne Portales; Emmanuelle Samalin; Simon Thezenas; Frédéric Viret; Marc Ychou
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
The oncologist 2011;16(11):1557-64.
2011: jean leon lagrange; Caroline Bascoul-Mollevi; Lionnel Geoffrois; Véronique Beckendorf; Jean-Marc Ferrero; Florence Joly; Nedjila Allouache; Jean-Marc Bachaud; Christine Chevreau; Andrew Kramar; Bruno Chauvet
Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).
International journal of radiation oncology, biology, physics 2011;79(1):172-8.
2010: William Jacot; Frédéric Bibeau; Sophie Gourgou-Bourgade; Marian Gutowski; Pierre-Emmanuel Colombo; Jean-Pierre Bleuse; Andrew Kramar; Gilles Romieu
Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
American journal of clinical oncology 2010;33(6):544-9.
2010: Anja Lorch; Jörg Beyer; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence H Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim A Margolin; Jean-Pierre Lotz; Jose Ramon Germa Lluch; Thomas Powles; Christian K Kollmannsberger
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(33):4906-11.
2010: Nadine Houede; Peter F Thall; Hoang Nguyen; Xavier Paoletti; Andrew Kramar
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials.
Biometrics 2010;66(2):532-40.
2009: Caroline Desmetz; Caroline Bascoul-Mollevi; Philippe Rochaix; Pierre-Jean Lamy; Andrew Kramar; Philippe Rouanet; Thierry Maudelonde; Alain Mangé; Jerome Solassol
Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(14):4733-41.
2008: Virginie Granci; Frédéric Bibeau; Andrew Kramar; Florence Boissière-Michot; Simon Thézénas; Agnès Thirion; Céline Gongora; Pierre Martineau; Maguy Del Rio; Marc Ychou
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.
European journal of cancer (Oxford, England : 1990) 2008;44(15):2312-8.
2008: Simone Mathoulin-Pelissier; Sophie Gourgou-Bourgade; Franck bonnetain; Andrew Kramar
Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(22):3721-6.
2008: Marc Ychou; F Viret; Andrew Kramar; F Desseigne; E Mitry; Rosine Guimbaud; J R Delpero; M Rivoire; F Quénet; G Portier; B Nordlinger
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Cancer chemotherapy and pharmacology 2008;62(2):195-201.
2008: J F Bourgeois; Sophie Gourgou; Andrew Kramar; Jean-Michel Lagarde; B Guillot
A randomized, prospective study using the LPG technique in treating radiation-induced skin fibrosis: clinical and profilometric analysis.
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 2008;14(1):71-6.
2007: Maguy Del Rio; Franck Molina; Caroline Bascoul-Mollevi; Virginie Copois; Frédéric Bibeau; Patrick Chalbos; Corinne Bareil; Andrew Kramar; Nicolas Salvetat; Caroline Fraslon; Emmanuel Conseiller; Virginie Granci; Benjamin Leblanc; Bernard Pau; Pierre Martineau; Marc Ychou
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):773-80.
2007: Virginie Copois; Frédéric Bibeau; Caroline Bascoul-Mollevi; Nicolas Salvetat; Patrick Chalbos; Corinne Bareil; Laurent Candeil; Caroline Fraslon; Emmanuel Conseiller; Virginie Granci; Pierre Mazière; Andrew Kramar; Marc Ychou; Bernard Pau; Pierre Martineau; Franck Molina; Maguy Del Rio
Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality.
Journal of biotechnology 2007;127(4):549-59.
2007: Majida Esslimani-Sahla; Simon Thezenas; Joelle Simony-Lafontaine; Andrew Kramar; Roselyne Lavaill; Dany Chalbos; Henri Rochefort
Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis.
International journal of cancer. Journal international du cancer 2007;120(2):224-9.
2005: Mahmut Ozsahin; Nigel E A Crompton; Sophie Gourgou; Andrew Kramar; Ling Li; YuQuan Shi; Wendy Jeannerez Sozzi; Abderrahim Zouhair; René-Olivier Mirimanoff; David Azria
CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7426-33.
2005: Caroline Bascoul-Mollevi; Sophie Gourgou-Bourgade; Andrew Kramar
Two-part statistics with paired data.
Statistics in medicine 2005;24(9):1435-48.
2005: Majida Esslimani-Sahla; Andrew Kramar; Joelle Simony-Lafontaine; Margaret Warner; Jan-�ke GUSTAFSSON; Henri Rochefort
Increased estrogen receptor betacx expression during mammary carcinogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3170-4.
2005: Philippe Rouanet; Gustavo Linares-Cruz; François Dravet; Sylvain Poujol; Sophie Gourgou; Joelle Simony-Lafontaine; Jean Grenier; Andrew Kramar; Jean Girault; Elisabeth Le Nestour; Thierry Maudelonde
Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2980-7.
2005: Andrew Kramar; Sophie Gourgou-Bourgade; Marc Ychou
Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):650; author reply 650-1.
2004: David Azria; Sophie Gourgou; Wendy Jeannerez Sozzi; Abderrahim Zouhair; René-Olivier Mirimanoff; Andrew Kramar; Claire Lemanski; Jean-Bernard Dubois; Gilles Romieu; Andre Pelegrin; Mahmut Ozsahin
Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients.
British journal of cancer 2004;91(7):1251-60.
2004: Majida Esslimani-Sahla; Joelle Simony-Lafontaine; Andrew Kramar; Roselyne Lavaill; Caroline Mollevi; Margaret Warner; Jan-�ke GUSTAFSSON; Henri Rochefort
Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5769-76.
2004: Simon Thezenas; Jacqueline Duffour; Stéphane Culine; Andrew Kramar
Five-year change in statistical designs of phase II trials published in leading cancer journals.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1244-9.
2004: Sylvaine Galiègue; Pierre Casellas; Andrew Kramar; Norbert Tinel; Joelle Simony-Lafontaine
Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):2058-64.
2003: David Azria; Christel Larbouret; Véronique Garambois; Andrew Kramar; Pierre Martineau; Bruno Robert; N Aillères; Marc Ychou; Jean-Bernard Dubois; André Pèlegrin
Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer.
British journal of cancer 2003;89(10):1987-94.
2003: Marc Ychou; Jacqueline Duffour; Andrew Kramar; Charles Debrigode; Sophie Gourgou; Françoise Bressolle; Frédéric Pinguet
Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Cancer chemotherapy and pharmacology 2003;52(4):282-90.
2003: Hubert Vidal; Guillaume Mondesert; Sylvaine Galiègue; Dominique Carrière; Pascal-Henri Dupuy; Pierre Carayon; Thérèse Combes; Estelle Bribes; Joelle Simony-Lafontaine; Andrew Kramar; Gérard Loison; Pierre Casellas
Identification and pharmacological characterization of SRBP-2: a novel SR31747A-binding protein.
Cancer research 2003;63(16):4809-18.
2003: Marc Ychou; Thierry Conroy; Jean-François Seitz; Sophie Gourgou; Aliette Hua; D Mery-Mignard; Andrew Kramar
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(3):481-9.
2003: J F Bourgeois; Sophie Gourgou; Andrew Kramar; Jean-Michel Lagarde; Y Gall; B Guillot
Radiation-induced skin fibrosis after treatment of breast cancer: profilometric analysis.
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 2003;9(1):39-42.
2002: Stéphane Culine; Andrew Kramar; Mahasti Saghatchian; Roland Bugat; Thierry Lesimple; Alain Lortholary; Yacine Merrouche; Agnès Laplanche; Karim Fizazi
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(24):4679-83.
2002: Jacqueline Duffour; Sophie Gourgou; Jean-François Seitz; Pierre Senesse; O Boutet; D Castera; Andrew Kramar; Marc Ychou
Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer.
Anticancer research 2002;22(6B):3727-31.
2002: Marc Ychou; Jean-Luc Raoul; Françoise Desseigne; C Borel; F X Caroli-Bosc; Jacques-Henri Jacob; Jean-François Seitz; Andrew Kramar; Aliette Hua; P Lefebvre; C Couteau; Yacine Merrouche
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Cancer chemotherapy and pharmacology 2002;50(5):383-91.
2002: Pierre-Jean Lamy; Pascal Pujol; Simon Thezenas; Andrew Kramar; Philippe Rouanet; Françoise Guilleux; Jean Grenier
Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy.
Breast cancer research and treatment 2002;76(1):65-71.
2002: Philippe Rouanet; Bernard Saint-Aubert; Claire Lemanski; Pierre Senesse; Sophie Gourgou; François Quenet; Marc Ycholu; Andrew Kramar; JeanBernard Dubois
Restorative and nonrestorative surgery for low rectal cancer after high-dose radiation: long-term oncologic and functional results.
Diseases of the colon and rectum 2002;45(3):305-13; discussion 313-5.
2001: Marc Ychou; F Khemissa-Akouz; Andrew Kramar; Pierre Senesse; Jean Grenier
[A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma].
Bulletin du cancer 2001;88(10):1023-7.
2000: Joelle Simony-Lafontaine; M Esslimani; Estelle Bribes; Sophie Gourgou; N Lequeux; R Lavail; Jean Grenier; Andrew Kramar; Pierre Casellas
Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors.
British journal of cancer 2000;82(12):1958-66.
2000: Marc Ychou; Jacqueline Duffour; Andrew Kramar; Sophie Gourgou; Jean Grenier
Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
Disease markers 2000;16(3-4):105-10.
1999: Marc Ychou; Jacqueline Duffour; Frédéric Pinguet; Andrew Kramar; JM Joulia; D Topart; Françoise Bressolle
Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer.
Anticancer research 1999;19(3B):2229-35.
1998: Marc Ychou; Jacqueline Duffour; Andrew Kramar; Jean Grenier
Value of serial carcinoembryonic antigen levels in evaluating the response to chemotherapy in patients with advanced digestive cancers.
Oncology reports 1998;5(5):1245-50.
1997: Stéphane Culine; Michel Fabbro; C Assens; Marc Ychou; Gilles Romieu; Andrew Kramar; Didier Cupissol; Frédéric Pinguet; H Pujol
Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):951-6.